The emergence of antibody-drug conjugates (ADCs) as a potential therapeutic avenue in cancer treatment has garnered significant attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drug molecules,Read More…
Optimization Strategies for Dose Adjustment Due to the dose-dependent nature of adverse reactions in ADC therapies, optimizing safety can be achieved through dose adjustment strategies. These include setting dose limits, maximum treatmentRead More…
Recently, Pfizer announced that it would buy Seagen for $229 a share in cash, for a total price of about $43 billion. According to the company’s website, Seagen currently has three ADCRead More…
Receptor-mediated Uptake Mechanism The target-dependent uptake and toxicity of ADC can also be mediated by different receptors that recognize the Fc (fragment crystallization) region of the IgG part of ADC. The constantRead More…
Nonspecific endocytosis Endocytosis is an important process in cell uptake of nutrients, regulation of transmembrane kinetics, synaptic vesicle recycling, and so on. Endocytosis can also play an important role in the uptakeRead More…
Linker-Unstable Payload Connection Connector-payload instability can cause the payload to be released prematurely into the bloodstream and lead to ADC miss toxicity. The choice of connectors is one of the main driversRead More…
So far, a total of 16 ADC drugs have been approved worldwide, and one (trastuzumab duocarmazine) is still in the stage of applying for listing. In recent years, with the significant increaseRead More…
Creative Biolabs, one of the industry-pioneering CROs holding specialties in bioconjugate, participated in the 13th Annual World ADC Summit last week and announced the successful accomplishment of its journey in San Diego.Read More…
When we get an ideal candidate for ADC, the next step is to consider how to scale it up. This step is important because it is directly related to the post-market marketRead More…
Specific Binding ADC drugs specifically bind to antigenic epitopes of cancer cells through their “guiding” antibodies, and enter into cancer cells through antigen-mediated endocytosis, then release the “warheads” – highly active cytotoxicRead More…